Does insulin still have a place in the management of hyperglycaemia in T2D?
Insulin, our first pharmacotherapeutic agent and King, is almost a centenarian – but is it time for the old King to abdicate? Are GLP1-RAs the rightful heirs to the injectable kingdom or simply adolescent upstarts needing to earn their right to the throne?
Join us for this lively and entertaining MEDTalk presented by three prominent GPs with deep expertise in diabetes as they debate whether, in this new realm of diabetes management, the older sovereign, insulin, should now be consigned to the retirement village of history.
- Analyse updated recommendations in new Australian and international T2D management guidelines in relation to injectable therapies.
- Develop a person-centred model of T2D care to optimise both individual quality of life and clinical outcomes.
- Identify clinical situations where GLP1-RA and insulins may provide improved outcomes in T2D management.
- Apply the most appropriate injectable therapy to provide optimal person-centred T2D care.
Ear yourself 3 RACGP points/1.5 hours or 2 ACRRM CPD hours by participating in this high-impact webinar.
If you are interested in joining the webinar, you can register by clicking the button below.
Register here: http://news.reedmedicaleducation.com.au/gpcemedtalkswebinar